TR201704362A2 - THE USE OF A HERBAL FORMULATION CONTAINING LINEN SEED OIL IN THE TREATMENT OF CHRONIC CONSTIPATION - Google Patents

THE USE OF A HERBAL FORMULATION CONTAINING LINEN SEED OIL IN THE TREATMENT OF CHRONIC CONSTIPATION Download PDF

Info

Publication number
TR201704362A2
TR201704362A2 TR2017/04362A TR201704362A TR201704362A2 TR 201704362 A2 TR201704362 A2 TR 201704362A2 TR 2017/04362 A TR2017/04362 A TR 2017/04362A TR 201704362 A TR201704362 A TR 201704362A TR 201704362 A2 TR201704362 A2 TR 201704362A2
Authority
TR
Turkey
Prior art keywords
treatment
oil
capsule
constipation
chronic constipation
Prior art date
Application number
TR2017/04362A
Other languages
Turkish (tr)
Inventor
Büyükhelvacigi̇l Mevlüt
Original Assignee
Helvacizade Gida Ilac Kimya Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helvacizade Gida Ilac Kimya Sanayi Ve Ticaret Anonim Sirketi filed Critical Helvacizade Gida Ilac Kimya Sanayi Ve Ticaret Anonim Sirketi
Priority to TR2017/04362A priority Critical patent/TR201704362A2/en
Publication of TR201704362A2 publication Critical patent/TR201704362A2/en
Priority to PCT/TR2018/050101 priority patent/WO2018226190A2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/55Linaceae (Flax family), e.g. Linum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

İlaç sektöründe; bitkisel Omega 3 yağ asidi olan alfa-linolenik asit (ALA) açısından zengin keten tohumu yağı içeren bitkisel formülasyonun kronik konstipasyon (kabızlık) tedavisinde kullanılabilmesi ile ilgilidir. Bahsedilen bitkisel formülasyon, keten tohumu yağı, dl a-tokoferol, dl a-tokoferil asetat, gliserin, saf su ve içeriğin bütünlüğünü ve kapsül oluşumunu sağlayan jelatin içermektedir.In the pharmaceutical sector; Vegetable Omega 3 fatty acid alpha-linolenic acid (ALA) rich in flaxseed oil containing herbal formulation can be used in the treatment of chronic constipation (constipation). Said vegetable formulation comprises flaxseed oil, dl α-tocopherol, dl α-tocopheryl acetate, glycerin, purified water and gelatin which provides the integrity of the contents and capsule formation.

Description

TEKNIK ALAN Bu bulus, kimya sektöründe, ilaç endüstrisinde keten tohumu yagi (Oleum Lini) içeren bir bitkisel formülasyonun kullanimi ile ilgilidir. TECHNICAL FIELD This invention is a product containing linseed oil (Oleum Lini) in the chemical industry, pharmaceutical industry. relates to the use of the herbal formulation.

Bulus özellikle bitkisel Omega 3yag asidi olan alfa-Iinolenik asit (ALA) açisindan zengin keten tohumu yagi ile hazirlanan; antioksidan özellige sahip yumusak kapsül halindeki bir bitkisel formülasyonun kronik konstipasyon (kabizlik) tedavisinde kullanimi ile ilgilidir. The invention is rich in alpha-linolenic acid (ALA), which is a vegetable Omega 3 fatty acid. prepared with linseed oil; A soft capsule with antioxidant properties. It relates to the use of herbal formulation in the treatment of chronic constipation.

TEKNIGIN BILINEN DURUMU Omega 3, bir esansiyel yag asidi olup, diger esansiyel yag asitleri gibi organizmanin yasamini devam ettirebilmesi için disaridan alinmasi gereken, vücutta sentezlenemeyen bir yag asididir. Bu esansiyel yag asidi besinler yolu ile veya bazi takviyeler ile organizmaya alinmalidir. Disaridan organizmaya alinan bitkisel Omega 3 yag asidi olan ALA; balik yagi kullanamayan kisilerde özellikle vejetaryenlerde bitkisel omega 3 (ALA) kaynagi olarak kullanilabilir ve kronik konstipasyon (kabizlik) tedavisine, bazi kan Iipid (yag) seviyelerinin düzenlenmesine, kalp-damar sistemi hastaliklarinin ve hafif gastrointestinal rahatsizliklarin tedavisine yardimci olarak görev yapmaktadir. KNOWN STATE OF THE TECHNIQUE Omega 3 is an essential fatty acid and, like other essential fatty acids, it is essential for the organism. It is a substance that cannot be synthesized in the body, which must be taken from the outside in order to continue its life. is fatty acid. This essential fatty acid is supplied to the organism through foods or some supplements. should be taken. ALA, a vegetable Omega 3 fatty acid taken from the outside to the organism; Fish oil as a source of herbal omega 3 (ALA) in people who cannot use it, especially in vegetarians. It can be used and can be used for the treatment of chronic constipation (constipation), some blood lipid (fat) levels regulation of cardiovascular diseases and mild gastrointestinal disorders. He works as a treatment assistant.

Mevcut teknikte; kronik konstipasyon (kabizlik) tedavisinde tedaviye yardimci olarak kullanilan ürünlerde sentetik madde veya belli oranlarda kimyasal madde bulunmaktadir. In the current technique; as an adjunct to treatment in the treatment of chronic constipation There are synthetic substances or chemicals in certain proportions in the products used.

Sentetik ve kimyasal maddelerin kullanimi organizmada birçok yan etkilere neden olarak vücudun birçok sistemini kötü yönde etkileyebilmektedir. The use of synthetic and chemical substances causes many side effects in the organism. It can adversely affect many systems of the body.

Ayrica mevcut uygulamalarin birçogunda ürünler sivi formda bulunmaktadir. Bu durum kontrollü dozlamanin yapilmasini güçlestirmektedir. Bu nedenle gerekli doz, tam ve net olarak saglanamamaktadir. Also, in many of the current applications, the products are available in liquid form. This situation makes controlled dosing difficult. Therefore, the required dose is complete and clear. cannot be provided.

Literatürde, konu ile ilgili yer alan patentlerden biri; CN103099755 numarali basvurudur. Bu bulus içerisinde keten tohumu da bulunan birçok bitkisel malzeme ile yapilan dogal, deriye zindelik ve yumusaklik veren bir banyo köpügünden bahsetmektedir. In the literature, one of the patents on the subject; Reference number CN103099755. This Natural, leather made with many herbal materials including flaxseed in the invention. it talks about a bath foam that gives vitality and softness.

CN105560646 numarali basvuru ise, keten tohumunun yanisira içeriginde tüylü kiraz, demirhindi meyvesi, muz ejderha dili yapragi, carageen, Rus bochniakia otu, Japon dok kökleri, Nepal dok kökleri, radix Scrophulariae, radix Iithospemi, kahve, sinameki, olgunlasmamis aci ot, portakal, pakchoi genç bitkileri, saçkiran, sinameki ve seftali çiçekleri yapraklarinin da bulundugu kabizlik, düzensiz bagirsak hareketleri, zor diskilama, boncuk seklinde kuru diski gibi belirtileri tedavi etmek için gerçeklestirilen bitkisel bir karisimdan bahsetmektedir. Application numbered CN105560646, in addition to linseed, contains hairy cherry, tamarind fruit, banana dragon tongue leaf, carageen, Russian bochniakia grass, Japanese dock roots, Nepal dock roots, radix Scrophulariae, radix Iithospemi, coffee, senna, immature bitter herb, orange, pakchoi young plants, ringworm, senna and peach flowers constipation, irregular bowel movements, difficult defecation, bead from a herbal mixture made to treat symptoms such as dry disk in the form of is talking about.

Sonuç olarak yukarida anlatilan olumsuzluklardan dolayi ve mevcut çözümlerin konu hakkindaki yetersizligi nedeniyle kronik konstipasyon (kabizlik) tedavisi ile ilgili teknik alanda bir gelistirme yapilmasi gerekli kilinmistir. As a result, due to the above-mentioned negativities and existing solutions in the technical field related to the treatment of chronic constipation (constipation) an improvement is required.

BULUSUN AMACI Bulusun ana amaci, keten tohumu yagi formülasyonunun kronik konstipasyon (kabizlik) tedavisinde kullanilabilmesidir. OBJECTIVE OF THE INVENTION The main object of the invention is that the flaxseed oil formulation is used to treat chronic constipation. can be used in the treatment.

Formülasyon yapisinda Omega-3 yüksek oranda oi-Iinolenik asit (ALA, 18:3n-3) ve lignanlar içermektedir. Keten tohumu yagi açisindan zengin olan formülasyon, keten tohumunun içerigindeki lifli yapilar nedeniyle yetiskinlerde bagirsak hareketlerinin artirilmasina yardimci olmaktadir. Böylelikle diskilama sikligi ve sürekliliginin düzene girmesine, kabizligin giderilmesine ve kronik konstipasyon (kabizlik) tedavisine yardimci olarak kullanilabilmektedir. Omega-3 in its formulation structure, high ratio of oi-linolenic acid (ALA, 18:3n-3) and lignans contains. The formulation, which is rich in flaxseed oil, It helps to increase intestinal movements in adults due to the fibrous structures in its content. is happening. In this way, the frequency and continuity of defecation will be regulated, constipation can be prevented. as an aid in the relief and treatment of chronic constipation (constipation) can be used.

Bu bulusun diger bir amaci, olusturulan formülasyonun, hiçbir kimyasal madde içermeden, keten tohumu yaginin elde edilmesinde dahi herhangi bir isil ya da kimyasal islem uygulanmamaktadir. Böylece; bitkinin içerisindeki etken maddeler, besin degerleri, vitamin ve mineraller kaybolmadan direkt ürüne geçmektedir. Another aim of this invention is that the formulation formed does not contain any chemicals, No heat or chemical treatment, even in the production of linseed oil not applicable. Like this; active ingredients, nutritional values, vitamins and minerals pass directly to the product without being lost.

Bulusun bir diger amaci da kimyasal olmadan olusturulan içerik sayesinde insan sagligini kötü yönde etkileyecek yan etkilerin minimuma indirilmesinin saglanmasidir. Tamamen dogal ve bitkisel ürün kullanimiyla çok nadir olarak bulanti, kusma, ishal gibi sadece mide-bagirsak sistemini etkileyen yan etkiler gözlenmektedir. Another aim of the invention is to protect human health thanks to the content created without chemicals. It is to ensure that the side effects that will adversely affect are minimized. completely natural and very rarely with the use of herbal products, such as nausea, vomiting, diarrhea, only gastro-intestinal side effects affecting the system are observed.

Bu bulusun diger bir amaci, olusturulan formülasyonun kapsül formunda olmasiyla, hasta kompliyansi ve hasta uyuncu açisindan kullanim kolayliginin saglanmasidir. Ayrica, olusturulan kapsül formu sayesinde bahsedilen endikasyonlarda dozlamayi elde etmede avantaj saglanmaktadir. Another object of this invention is that the formulation formed is in capsule form, so that the patient It is to provide ease of use in terms of compliance and patient compliance. Moreover, in obtaining the dosing in the mentioned indications thanks to the capsule form created. advantage is provided.

BULUSUN DETAYLI AÇIKLAMASI Bu bulusun amacina ulasmak için gerçeklestirilen keten tohumu yagi kullanilarak elde edilmis bitkisel bir kapsül formülasyonunun tercih edilen kullanimi sadece konunun daha iyi anlasilmasina yönelik olarak ve hiçbir sinirlayici etki olusturmayacak sekilde açiklanmaktadir. DETAILED DESCRIPTION OF THE INVENTION To achieve the aim of this invention, it is obtained by using linseed oil made. The preferred use of an herbal capsule formulation that has been for understanding and without any limiting effect is explained.

Keten Tohumu Yagi: Keten tohumu içerisinde omega-3 (ALA) açisindan zengin yag ve Iignanlar bulunmaktadir. Flaxseed Oil: Flaxseed contains omega-3 (ALA) rich oil and lignans.

Tohumlardan elde edilen yaglar arasinda keten tohumu yagi yüksek oranda oi-Iinolenik asit (ALA, 18:3n-3) ve Iignan bulundurmasindan dolayi ön plana çikmaktadir. Keten tohumunda olusmaktadir. ALA, omega-3 grubu yag asidi olarak siniflandirilmaktadir. Among the oils obtained from the seeds, linseed oil has a high content of oi-linolenic acid. (ALA, 18:3n-3) and Iignan. In flaxseed is formed. ALA is classified as omega-3 fatty acid.

Keten tohumu yagi bilesimindeki ALA nedeniyle pek çok farkli farmakolojik etki göstermektedir. Keten tohumu yagi içeren formülasyon, keten tohumunun içerigindeki lifli yapilar nedeniyle yetiskinlerde bagirsak hareketlerinin artirilmasina yardimci olmaktadir. Many different pharmacological effects due to the ALA in the flaxseed oil composition. shows. The formulation containing flaxseed oil contains fibrous content of flaxseed. It helps to increase intestinal movements in adults due to the structures.

Böylelikle diskilama sikligi ve sürekliliginin düzene girmesine, kabizligin giderilmesine ve kronik konstipasyon (kabizlik) tedavisine yardimci olarak kullanilabilmektedir. Thus, it helps to regulate the frequency and continuity of defecation, eliminate constipation and It can be used as an aid in the treatment of chronic constipation.

Keten tohumu yagi, serum total kolesterol düzeylerinde % 15 oraninda azalmaya neden olmaktadir. Yine yüksek oranda ALA tasiyan keten tohumu yagi kullanimin hiperlipidemik kisilerde serum total kolesterol, LDL (düsük dansiteli Iipoprotein) düzeyini azaltmaktadir. Flaxseed oil causes a 15% reduction in serum total cholesterol levels. is happening. Again, the use of flaxseed oil, which has a high level of ALA, is associated with hyperlipidemic It reduces serum total cholesterol and LDL (low-density Iipoprotein) levels in individuals.

Postmenopozal kadinlarda da LDL kolesterol düzeylerinde ayni sekilde azalma görülmüstür. A similar decrease was observed in LDL cholesterol levels in postmenopausal women.

Bu etkiye keten tohumundan izole edilen, memelilerde bulunan enterodiol ve enterolakton adli Iignanlarin öncü maddeleri olan SDG (sekoizolarisiresinol diglukozid) bilesigi neden olmaktadir ve serum total kolesterol miktarinda %33, aterosklerotik plaklarda %73 oraninda azalma meydana gelmistir. Keten tohumu yaginin bu etkileri ateroskleroz gelisimini engelleyici ve kan Iipid seviyelerini düzenleyici etkilerini açiklamaktadir. Enterodiol and enterolactone isolated from flaxseed and found in mammals have this effect. The compound SDG (secoisolariciresinol diglucoside), which is the precursor of forensic lignans, causes It is found to be 33% in serum total cholesterol and 73% in atherosclerotic plaques. reduction has occurred. These effects of flaxseed oil prevent the development of atherosclerosis. explains the inhibitory and regulating effects of blood lipid levels.

Keten tohumu yaginin antitrombotik etkileri ve trombositlerin agregasyonunu azaltici etkilerinin olmasindan dolayi tromboz insidansinin azalmasina yardimci olabilmektedir. Antithrombotic effects of flaxseed oil and reducing platelet aggregation It may help to reduce the incidence of thrombosis due to its effects.

Keten tohumu yagi içerigindeki ALA nedeniyle antioksidan etki göstermektedir. Ayrica ALAlnin Interlökin, TNF (Tümör nekrozis faktör), lökotrien B4 ve polimorfonükleer lökositler üzerine supresör etkileri vardir. Bu etkileri keten tohumu yaginin inflamasyonun gelisimini inhibe edici etkilerini açiklamaktadir. Flaxseed oil has an antioxidant effect due to its ALA content. Moreover ALAlnin Interleukin, TNF (Tumor necrosis factor), leukotriene B4 and polymorphonuclear leukocytes has suppressor effects. These effects of flaxseed oil improve the development of inflammation. explains its inhibitory effects.

Keten tohumu yaginin kalsiyum emilimini arttirdigi bilinmektedir. Bu etkisi ile birlikte kemik sagligina da yardimci etkileri vardir. Flaxseed oil is known to increase calcium absorption. With this effect, the It also has beneficial effects on health.

Ayrica balik yagi kullanamayan yetiskinler özellikle vejetaryenler için keten tohumu yagi, bitkisel Omega 3 destegi olmasi bakimindan önemlidir. In addition, flaxseed oil for adults, especially vegetarians, who cannot use fish oil, It is important in terms of having herbal Omega 3 support.

Kapsül formülasvon içerigi: Formülasyonda, etken madde olarak keten tohumu yagi, yardimci maddeler olarak ise dl oi- tokoferol, dl oi-tokoferil asetat, gliserin, saf su ve jelatin kullanilmaktadir. dl d-tokoferol ve di d-tokoferil asetat koruyucu madde görevinde kullanilmaktadir. Söz konusu formülasyona; dl oi-tokoferol, dl d-tokoferil asetat, ppm düzeyinde katilmaktadir. Içerigin bütünlügünü saglamak üzere kullanilan jelatin için ise; sigir jelatini kullanilmaktadir. Jelatine alternatif olarak, hayvansal kaynakli ve bitkisel digerjelatinler kullanilabilir. Capsule formulation content: In the formulation, linseed oil as active ingredient and dl oil as auxiliary substances. tocopherol, dl oi-tocopheryl acetate, glycerin, purified water and gelatin are used. dl d-tocopherol and di d-tocopheryl acetate is used as a preservative. The formulation in question; dl oi-tocopherol, dl d-tocopheryl acetate are added at ppm level. the integrity of the content For the gelatin used to provide; bovine gelatin is used. Alternative to gelatin As an alternative, other gelatins of animal origin and vegetable origin can be used.

Tablo 1'de de belirtildigi üzere; içerikte agirlikça %42,050 oraninda keten tohumu yagi, Tablo 1. Kapsülün içerigi ve agirlikça yüzdeleri Tercih edilen agirlikça Kullanilabilir agirlikça Hammadde miktar (%) Miktar (mg) Keten tohumu yagi 42,050 625 dl d-tokoferol 0,004 0,047 dl d-tokoferil asetat 0,021 0, 312 Gliserin 10,831 161 Su 23,547 350 Jelatin 23,547 350 Kapsülün üretim yöntemi: Kapsül formülasyonunun üretim basamaklari söyledir: hammaddelerden bir tanesi olan, keten tohumu, eleme isleminden geçirilmektedir. Eleme isleminin ardindan gerekirse kirma islemi gerçeklestirilmektedir. Keten tohumu, söz konusu islemlerden geçirilip istenilen boyutun elde edilmesinin ardindan, soguk pres ünitesine gönderilmektedir. Soguk pres yöntemi ile hammaddeden yag çikarilmasi islemi gerçeklestirilmektedir. Söz konusu yöntemde 55 °C`nin üstüne çikilmamalidir. Soguk pres ünitesinden gelen yag, filtrasyon isleminden önce karistirma ve dinlendirme tanklarinda tutulmaktadir. Böylece olasi partiküllerin, karistirma ve dinlenme islemleriyle ayrilmasi kolaylasmaktadir. Çikarilan yag; karistirma ve dinlenme tanklarindan sonra, kapali ortamda ve oda sicakliginda filtre ünitesine beslenmektedir. Filtre ünitesinde, varsa yag içeriginde bulunan partiküller filtre edilmektedir. Filtrasyon asamasindan sonra, elde edilen yaga; koruyucu madde olarak dl oi- tokoferol ve di oi-tokoferil asetat eklenmektedir. Böylece içerigi olusturan karisim elde edilmektedir. As stated in Table 1; flaxseed oil at a rate of 42.050% by weight, Table 1. Contents and weight percentages of the capsule Preferred weight By weight usable Raw material quantity (%) Quantity (mg) Linseed oil 42,050 625 dl d-tocopherol 0.004 0.047 dl d-tocopheryl acetate 0.021 0.312 Glycerin 10,831 161 water 23.547 350 Gelatin 23.547 350 Production method of the capsule: The production steps of the capsule formulation are as follows: one of the raw materials, flaxseed is passed through the sieving process. Crushing if necessary after elimination operation is carried out. Flaxseed is passed through the aforementioned processes and the desired After the size is obtained, it is sent to the cold press unit. Cold press The process of extracting oil from the raw material is carried out by the method. Aforementioned In this method, it should not be exceeded 55 °C. Oil from the cold press unit, filtration It is kept in mixing and resting tanks before processing. Thus possible It is easier to separate the particles by mixing and resting processes. extracted oil; after mixing and resting tanks, indoors and at room temperature is fed to the filter unit. In the filter unit, the particles in the oil content, if any, are filtered. is being done. After the filtration step, the obtained oil; dl oi- as preservative tocopherol and di-tocopheryl acetate are added. Thus, the mixture that makes up the content is obtained. is being done.

Bu islemler gerçeklestirilirken diger taraftan; jelatin hazirlama ünitesinde, kapsül bütünlügünün saglanmasi için kullanilan jelatin hazirlanmaktadir. While these transactions are being carried out, on the other hand; in the gelatin preparation unit, the capsule The gelatin used to ensure its integrity is being prepared.

Karisimin olusturulmasi ve jelatinin hazirlanmasinin akabinde, kapsül üretim ünitesine gönderilerek istenilen dozajda kapsüller hazirlanmaktadir. Bahsedilen kapsül, yumusak jelatin kapsüldür. After the mixture is formed and the gelatine is prepared, it is sent to the capsule production unit. capsules are prepared in the desired dosage. Said capsule, soft gelatin capsule.

Kapsül hazirlandiktan sonra kurutma islemi gerçeklestirilmektedir. Kurutulmus kapsüller ambalajlanmaktadir. After the capsule is prepared, the drying process is carried out. dried capsules is being packaged.

Kapsülün Kullanim Talimati: Terapötik Endikasyonlari: Kapsül, bitkisel kaynakli Omega 3 yag asidi olan alfa-linolenik asit (ALA) açisindan zengindir. Kronik konstipasyonu olan hastalarda tedaviye yardimcidir. Capsule Usage Instructions: Therapeutic Indications: Capsule, plant-derived Omega 3 fatty acid, alpha-linolenic It is rich in acid (ALA). It helps in the treatment of patients with chronic constipation.

Ayrica, kalp-damar sistemi hastaliklarinda, bazi kari Iipid (yag) seviyelerinin düzenlenmesinde ve hafif gastrointestinal rahatsizliklarda tedaviye yardimcidir. Kapsül, balik yagi kullanamayan kisilerde özellikle vejetaryenlerde bitkisel omega 3 (ALA) kaynagi olarak da kullanilabilir. In addition, in diseases of the cardiovascular system, some anti-Iipid (fat) levels It helps to regulate and treat mild gastrointestinal disorders. capsule, fish As a vegetable omega 3 (ALA) source in people who cannot use oil, especially in vegetarians. can also be used.

Dozai ve Uygulama Yöntemi: Dozaj uygulama sikligi ve süresi: Doktor tarafindan baska bir sekilde tavsiye mg/gün dozda) oral yolla alinir. Kapsül 12 yas üstü çocuklarda günde 1-2 kapsül (625-1250 mg/gün) olarak kullanilabilir. Dosage and Administration Method: Dosage frequency and duration of administration: Otherwise recommended by the doctor mg/day dose) is taken orally. Capsules 1-2 capsules per day for children over 12 years old It can be used as (625-1250 mg/day).

Uygulama Yöntemi: Kapsüller agizda ezilmeden veya çignenmeden yeterli miktarda su ile tercihen tok karnina yutulmalidir. gel Popülasvonlara iliskin Ek Bilgiler: Böbrek/karaciger yetmezligi: Böbrek ve karaciger hastalarinda yapilmis yeterli güvenlilik çalismasi olmadigindan bu hasta gruplarinda kullanilmamalidir. Method of Application: Capsules in sufficient amount without crushing or chewing in the mouth It should be swallowed with water, preferably on a full stomach. gel Additional Information on Populations: Kidney/liver failure: Not enough done in kidney and liver patients. Since there is no safety study, it should not be used in these patient groups.

Pediyatrik popülasyonz12 yasin altindaki çocuklarda yapilmis yeterli güvenlilik çalismasi bulunmadigindan 12 yas alti çocuklarda kullanimi önerilmemektedir. Adequate safety studies have been performed in children under 12 years of age in the pediatric population. Since there is no study, its use is not recommended in children under 12 years of age.

Geriatrik popülasyon: Yaslilarda yapilmis yeterli güvenlilik çalismasi bulunmamaktadir. Ancak doz ayarlamasina gerek olmadigi düsünülmektedir. Geriatric population: Adequate safety studies in the elderly does not exist. However, it is thought that no dose adjustment is necessary.

Kontrendikasyonlar: Etkin madde Keten tohumu veya kapsülün içerdigi herhangi bir bilesenine alerjisi olanlarda, Gebelikte ve Iaktasyonda, Karaciger ve böbrek yetmezligi olan hastalarda, Tanisi konmamis rektal kanamasi olanlarda, Laksatif kullanimi sonrasi defekasyon bozuklugu olanlarda, Barsak aliskanliginda 2 haftadan daha uzun süredir ani degisim gözlenen hastalarda, Barsak paralizisi, megakolonu ve ileusu olan hastalarda kullanilmamalidir. Contraindications: Active ingredient Allergy to flaxseed or any ingredient contained in the capsule. in those, In pregnancy and lactation, In patients with liver and kidney failure, In patients with undiagnosed rectal bleeding, In those with defecation disorder after laxative use, In patients with sudden changes in bowel habits for more than 2 weeks, It should not be used in patients with intestinal paralysis, megacolon and ileus.

Kullanim için Özel Uyarilar ve Önlemler: Her bir kapsül 0,161 9 gliserin içermektedir. Ancak bu dozda gliserine bagli herhangi bir yan etki beklenmemektedir. Special Warnings and Precautions for Use: Each capsule contains 0.161 9 glycerin. However, at this dose, any side effects due to glycerin no effect is expected.

Oral antikoagülan ilaç kullanan hastalarda kapsülün günlük dozunun 3 g'i asmamasi gerekmektedir. Östrojenik etkisinden dolayi hormona bagli tümörlerin tedavisi esnasinda dikkatli kullanilmalidir. The daily dose of the capsule should not exceed 3 g in patients using oral anticoagulant drugs. required. Due to its estrogenic effect, it should be used with caution during the treatment of hormone-dependent tumors. should be used.

Barsak paralizisi ve ileusu olan hastalarda doktor kontrolünde kullanilmalidir. It should be used under the supervision of a doctor in patients with intestinal paralysis and ileus.

Kapsülün 1 haftadan daha uzun süreli kullaniminin doktora danisilarak sürdürülmesi önerilmektedir. Continuing the use of the capsule for longer than 1 week in consultation with the doctor recommended.

Gebelik ve Laktasyon 0 Gebelik dönemi: Konuyla ilgili herhangi bir çalisma bulunmadigindan kullanilmamalidir. o Laktasyon dönemi: Laktasyonda güvenliligi gösterilmediginden Iaktasyonda kullanilmasi önerilmemektedir. lstenmeyen Etkiler: o Gastrointestinal Hastaliklar: Kapsülün kullanimi ile birlikte yaygin olarak meteorizm, çok nadir olarak anaflaksiye benzeyen asiri duyarlilik reaksiyonlari gözlenebilir. Pregnancy and Lactation 0 Pregnancy period: Since there is no study on the subject should not be used. o Lactation period: Since its safety in lactation has not been demonstrated, use is not recommended. Undesirable Effects: o Gastrointestinal Diseases: Commonly meteorism with the use of the capsule, Very rarely, hypersensitivity reactions resembling anaphylaxis can be observed.

Ayrica sikligi bilinmemekle birlikte bulanti, kusma ve ishal gözlenebilir. Nausea, vomiting and diarrhea may also be observed, although the frequency is not known.

Bunlarin disinda herhangi bir istenmeyen etki bildirilmemistir. Apart from these, no undesirable effects were reported.

Doz Asimi: Keten tohumu yagi ile ilgili olarak hiç doz asimi bildirilmemistir. Oral olarak kullanilan keten tohumu yagi iyi tolere edilebilir. Fakat keten tohumunun kendisinin oral olarak kullaniminda asiri doza bagli gaz, siskinlik gibi abdominal rahatsizliklara sebep olabilecegi bildirilmistir. Overdose: No overdose has been reported for flaxseed oil. Orally used flax seed oil is well tolerated. However, oral use of flaxseed itself It has been reported that overdose may cause abdominal discomfort such as gas and bloating.

Asiri doz alimi sonrasi herhangi bir bulgu ortaya çikarsa tedavi semptomatik ve destekleyici olmalidir. Spesifik bir antidotu ve eliminasyonunu arttirici bir yöntem yoktur. If any symptoms occur after an overdose, treatment should be symptomatic and supportive. should be. There is no specific antidote and no method to increase its elimination.

Saklama Kosullari: Ürünün raf ömrü 2 yil olarak belirlenmistir. Storage Conditions: The shelf life of the product is determined as 2 years.

Yukarida içerigi ve üretim yönteminden bahsedilen kapsül, Türkiye Cumhuriyeti Saglik Bakanligi otoritesince “Geleneksel Bitkisel Tibbi Ürün” olarak ruhsatlandirilmistir. Söz CORVITAL adiyla 625 mg yumusak kapsül olarak geçmektedir. Yukarida sayilan endikasyonlara ve Geleneksel Bitkisel Tibbi Ürün Yönetmeligine göre Türkiye Cumhuriyeti Saglik Bakanligi tarafindan RUHSATLANDIRILMIS Geleneksel Bitkisel bir Tibbi Üründür. The capsule, the content and production method of which is mentioned above, is a product of the Republic of Turkey Health It has been licensed as a "Traditional Herbal Medicinal Product" by the Ministry of Health. Promise It is known as CORVITAL as 625 mg soft capsules. listed above Republic of Turkey according to indications and Traditional Herbal Medicinal Product Regulation It is a Traditional Herbal Medicinal Product LICENSED by the Ministry of Health.

Piyasada belirtilen endikasyonlar için ruhsat almis, çok sayida sentetik kimyasal içeren ürün vardir. Fakat bu alanda saglik otoritelerince ruhsatlandirilmis bu endikasyonlari olan herhangi bir geleneksel bitkisel tibbi ürün bulunmamaktadir. Product containing many synthetic chemicals, licensed for indications specified in the market has. However, those with these indications licensed by the health authorities in this field There are no traditional herbal medicinal products.

Mevcut uygulamalarin çogunda; kötü hijyen kosullarinda üretim söz konusu iken ilgili formülasyon; Saglik Bakanligilnin bir ilaç fabrikasindan istedigi GMP (Good Manufacturing Practises) normlarinda üretilmektedir. In most of the existing applications; when production is under poor hygienic conditions, formulation; The GMP (Good Manufacturing) required by the Ministry of Health from a pharmaceutical factory It is produced in Practises) norms.

Bilindigi üzere bitkisel ürünlerde standardizasyonu saglamak çok zor bir islemdir. Ilgili formülasyonun; . Tohumunda; pestisit, aflatoksin, agir metal ve etkin maddelerin analizi, mikrobiyolojik kontroller yapilmistir. 0 Soguk pres yagda; etkin maddelerin analizi için yöntem gelistirilmesi, validasyon ve mikrobiyolojik kontrolleri yapilmistir. 0 Tasarimda; hangi ürün, hangi endikasyon, hangi doz, hangi dozaj formu olacagi hesaplanmistir. . Ön formülasyonda; hangi etkin madde/hangi yardimci maddenin analizi hangi mikrobiyolojik kontroller, hangi kalite kontrol parametreleri, hangi stabilite çalismalari, yapilacagi düsünülüp, ona göre bir sistem gelistirilmistir. o Stabilite çalismalarinda; ön görülen raf ömrü süresince belirlenen spesifikasyonlarina uygunlugunu kanitlayan stabilite çalismalari kanitlanmis olup; 25°C±2, % 60 ±5 nemde 24 aylik çalisma ve 40°C±2, % 75 ±5 nemde 6 aylik çalisma yapilmistir. Analitik test yöntemlerine iliskin validasyonlar ve datalari ve ambalaj spesifikasyonlari, etkilesimleri, analiz ve kontrol yöntemleri belirlenmistir. o Kapsül bazi ve iç materyallerinin hazirlanmasinda, içerik tayini (yag bilesenleri analizi), bazi vizkozite ve optik görünüs kontrolü vb. testler yapilmistir. o Üretim prosedüründe; kalitatif ve kantitatif içerik tayini, optik kontrol gibi in-proses kontroller ve içerik tayinleri, mikrobiyolojik analizler, optik kontrol gibi kalite kontrol prosedürleri uygulanmistir. Ayrica aktif bilesenin ve ürün örneginin HPLC analizleri yapilmis ve yag asit kompozisyonlari hesaplanmistir. Ayrica aktif maddenin kalibrasyon tablolari çikartilmistir. As it is known, standardization in herbal products is a very difficult process. Relating to formulation; . In the seed; analysis of pesticides, aflatoxins, heavy metals and active substances, microbiological checks have been made. 0 In cold pressed oil; method development, validation and analysis for the analysis of active substances. microbiological controls were made. 0 In design; Which product, which indication, which dose, which dosage form? calculated. . In pre-formulation; Which active substance/which excipient is analyzed which microbiological controls, which quality control parameters, which stability studies, It was thought to be done and a system was developed accordingly. o In stability studies; to the specifications determined during the anticipated shelf life. stability studies proving its suitability have been proven; At 25°C±2, 60% ±5 humidity 24 months of operation and 6 months of operation at 40°C ± 2, 75% ± 5% humidity. analytical testing validations and data on methods and packaging specifications, interactions, analysis and control methods have been determined. o Content determination (oil component analysis) in the preparation of capsule base and internal materials, some viscosity and optical appearance control etc. tests have been done. o In the production procedure; in-process such as qualitative and quantitative content determination, optical control quality control such as controls and content determinations, microbiological analysis, optical control procedures have been applied. In addition, HPLC analyzes of active ingredient and product sample and fatty acid compositions were calculated. In addition, the calibration of the active substance tables are removed.

Yukarida anlatilan islemler; bitkisel ürünlerin standardizasyonu açisindan çok önemli detaylardir ve bu üründe ayrintili olarak yapilmistir. Bu ürün Saglik Bakanligi gibi bir saglik otoritesince Geleneksel Bitkisel Tibbi bir ürünün farmakodinamik özellikleri ruhsatlanarak, onay almistir. Bu ürün Saglik Bakanligi gibi bir saglik otoritesince Geleneksel Bitkisel Tibbi bir ürünün KÜB'ü (Kisa Ürün Bilgisi - Prospektüsü) ve KT'si (Kullanma Talimati) ruhsatlanarak, onay almistir. Bu ürün Saglik Bakanligi gibi bir saglik otoritesince Geleneksel Bitkisel Tibbi bir ürünün kullanim sekli ve dozu standart hale getirilip ruhsatlandirilarak, onay almistir. Bu anlamda Saglik Bakanligi ruhsatli geleneksel bitkisel tibbi bir ürünün klinik çalismalara uygun bir sekilde dozlamasi yazili hale getirilip saglik otoritelerince onaylatilip resmiyet kazandirilmis ve dünya tibbinin hizmetine sunulmustur. The operations described above; very important for the standardization of herbal products are details and have been made in detail in this product. This product is approved by the Ministry of Health. By licensing the pharmacodynamic properties of a Traditional Herbal Medicinal product by the authority, has been approved. This product is approved by a health authority such as the Ministry of Health for Traditional Herbal Medicine. SPC (Short Product Information - Package Insert) and KT (Instructions for Use) of a product licensed and approved. This product is approved by a health authority such as the Ministry of Health. The way of use and dosage of a herbal medicinal product is standardized and licensed, and approval is obtained. has received. In this sense, the clinical practice of a traditional herbal medicinal product licensed by the Ministry of Health. Dosing in accordance with the studies is written and approved by the health authorities. It was made official and presented to the service of world medicine.

Claims (2)

ISTEMLER 1. Keten tohumu yagi içeren bir bitkisel formülasyonun kronik konstipasyon (kabizlik) tedavisinde kullanilan bir ilacin üretiminde kullanimidir. CLIENTS 1. It is the use of a herbal formulation containing flaxseed oil in the production of a drug used in the treatment of chronic constipation (constipation). 2. Istem 1'deki gibi bir kullanim olup özelligi; bahsedilen bitkisel formülasyonun keten tohumu yagi, dl oi-tokoferol, dl oi-tokoferil asetat, gliserin, saf su ve içerigin bütünlügünü ve kapsül olusumunu saglayan jelatin içermesidir. kullanilmasidir. dozunda kullanilmasidir. 5. Istem 2'ye uygun bir kullanim olup özelligi; oral yolla uygulanmasidir.2. It is a use as in Claim 1 and its feature is; said herbal formulation contains flaxseed oil, dl oi-tocopherol, dl oi-tocopheryl acetate, glycerine, purified water and gelatin which ensures the integrity of the content and capsule formation. is to be used. is to be used in moderation. 5. It is a use according to claim 2 and its feature is; oral administration.
TR2017/04362A 2017-03-23 2017-03-23 THE USE OF A HERBAL FORMULATION CONTAINING LINEN SEED OIL IN THE TREATMENT OF CHRONIC CONSTIPATION TR201704362A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TR2017/04362A TR201704362A2 (en) 2017-03-23 2017-03-23 THE USE OF A HERBAL FORMULATION CONTAINING LINEN SEED OIL IN THE TREATMENT OF CHRONIC CONSTIPATION
PCT/TR2018/050101 WO2018226190A2 (en) 2017-03-23 2018-03-16 Use of a herbal formulation containing linseed oil in the treatment of chronic constipation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2017/04362A TR201704362A2 (en) 2017-03-23 2017-03-23 THE USE OF A HERBAL FORMULATION CONTAINING LINEN SEED OIL IN THE TREATMENT OF CHRONIC CONSTIPATION

Publications (1)

Publication Number Publication Date
TR201704362A2 true TR201704362A2 (en) 2017-07-21

Family

ID=64558664

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2017/04362A TR201704362A2 (en) 2017-03-23 2017-03-23 THE USE OF A HERBAL FORMULATION CONTAINING LINEN SEED OIL IN THE TREATMENT OF CHRONIC CONSTIPATION

Country Status (2)

Country Link
TR (1) TR201704362A2 (en)
WO (1) WO2018226190A2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104288345B (en) * 2013-07-15 2018-08-24 湘北威尔曼制药股份有限公司 A kind of Chinese medicine composition and preparation method thereof of auxiliary reducing blood lipid
CN105079309B (en) * 2015-09-22 2021-06-22 青海百岁食品科技有限公司 Composition for relaxing bowel
CN105266162B (en) * 2015-11-17 2017-09-26 黑龙江省科学院大庆分院 A kind of natto capsule health food containing for having whole intestines concurrently and adjusting immunity

Also Published As

Publication number Publication date
WO2018226190A3 (en) 2019-02-07
WO2018226190A9 (en) 2019-04-11
WO2018226190A2 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
CN102762573A (en) Compounds, compositions and methods for protecting brain health in neurodegenerative disorders
SG172727A1 (en) Use of ginkgo complexes for the enhancement of cognitive functions and the alleviation of mental fatigue
US20210205236A1 (en) Therapeutic combinations of boswellia extract and cannabinoids
Misra et al. Management of high altitude pathophysiology
WO2002011744A1 (en) A strong antioxidant composite capsule containing grape seed extract opc and process for producing the same
TR201704362A2 (en) THE USE OF A HERBAL FORMULATION CONTAINING LINEN SEED OIL IN THE TREATMENT OF CHRONIC CONSTIPATION
Parnham et al. Mild plant and dietary immunomodulators
TR201704364A2 (en) THE USE OF A HERBAL FORMULATION CONTAINING LINEN SEED OIL IN THE TREATMENT OF LIGHT GASTROINTESTINAL DISEASES
TR201703736A2 (en) THE USE OF A VEGETABLE FORMULATION CONTAINING LINEN SEED OIL IN THE TREATMENT OF HEART Vascular SYSTEM DISEASES
Morazzoni et al. Use of a Ginkgo complexes for the enhancement of cognitive functions and the alleviation of mental fatigue
WO2013056508A1 (en) Pharmaceutical composition regulating blood fat and preparation process thereof
CA3167106A1 (en) Plant extract composition for the treatment of cardiovascular and metabolic diseases
TR201704755A2 (en) THE USE OF A VEGETABLE FORMULATION CONTAINING LINEN SEED OIL AS A VEGETABLE OMEGA 3 (ALA) SOURCE IN PEOPLE NOT USING FISH OIL
WO2018222164A2 (en) Use of an herbal formula containing pumpkin seed oil in bph treatment
TR201705831A2 (en) THE USE OF A VEGETABLE FORMULATION CONTAINING POMEGRANOUS SEED OIL TO REDUCE BLOOD FATS KNOWN AS TRIGLYCERITE
TR201703084A2 (en) THE USAGE OF A VEGETABLE FORMULATION CONTAINING PUMPKIN SEED OIL IN THE TREATMENT OF THE EXTREMELY ACTIVE BLADDER AND URINARY INCONTINENCE RELATED LOWER URINARY SYSTEM SYMPTOMS
RU2717537C1 (en) Dietary supplement
Ulloa del Carpio et al. Exploring the chemical and pharmacological variability of Lepidium meyenii: a comprehensive review of the effects of maca
WO2018222166A9 (en) Use of an herbal formulation containing linseed oil in the treatment of regulating some blood lipid (fat) levels
RU2414231C1 (en) Antioxidant
CN110522791A (en) Licorice isoamylene radical chromocor is preventing and treating the application in obesity
RU2243781C1 (en) Biologically active supplement for prophylaxis of cardiovascular diseases
Mirahmadi et al. A Ferns G, Mirinezhad MR, Baharara H, Hadizadeh F, Ghayour-Mobarhan M
CN105831316A (en) Doubao tea chewable tablets and preparation method thereof
CN111956744A (en) Application of sea-red rice skin in preparing medicine for resisting anhedonia behaviors